Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004167 · ClinicalTrials.gov registry record · NA
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
A NA study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06004167 is a NA study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06004167, a NA study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.
Conditions Studied
Interventions
- RADIATION Adaptive Bridging Radiation Therapy (ABRT)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-01-14 |
| Est. Completion | 2024-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06004167
The ClinicalTrials.gov registry entry for NCT06004167 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Adaptive Bridging Radiation Therapy (ABRT) is the first listed.
NCT06004167 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06004167 about?
NCT06004167 is a clinical study titled "Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)". Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administratio...
What is the current status of trial NCT06004167?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2024-01-14. Estimated completion is 2024-12-01.
What conditions does trial NCT06004167 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Refractory Lymphoma, Lymphoma, B-Cell.
What interventions are being tested in trial NCT06004167?
The interventions under investigation include: Adaptive Bridging Radiation Therapy (ABRT) (RADIATION).
Who is sponsoring clinical trial NCT06004167?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004167 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
RECRUITING · NA
-
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
RECRUITING · NA
-
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
-
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.